About the Company
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BIIB News
Biogen plots 30% Leqembi field force bump, omnichannel campaigns as launch enters new phase
Biogen and Eisai are ready to ramp up their Leqembi sales and marketing push. After a slow start, Biogen is now planning to ...
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
Biogen Inc. ( NASDAQ: BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 5:00 PM ET Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Alisha Alaimo ...
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
On Wednesday, Biogen Inc (NASDAQ:BIIB) reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44.
To be better at neuroscience, Biogen will invest outside the therapeutic area
To be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic area that has in recent ...
Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses.
Biogen Q1 2024 results surpass expectation despite revenue decline
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing ...
Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook
Biotechnology company Biogen Inc. (BIIB) reported Wednesday net income attributable to the company for the first quarter of $393.4 ...
Biogen gets grant for treatment of disorders responsive to ASK1 inhibition
Discover the groundbreaking patent by Biogen Inc for compounds targeting ASK1 in autoimmune disorders like multiple sclerosis. Explore the innovative formulas and methods for treating complex medical ...
Loading the latest forecasts...